Proposals for the reform of Sweden's health care system, revealed in a report (HSU 2000) from the Parliamentary Commission, are difficult to understand and are "a bad prescription," according to the Swedish Association of the Pharmaceutical Industry, LIF.
The main purpose of the proposed reforms is a reduction of public spending on drugs. The report states that this means in reality that patients must pay a higher proportion of drug costs, and it is underlined that in a longer perspective, the public costs for medical care and pharmaceuticals must be contained.
Proposed Copayment Fees Amount of Payment Copayment fee 0-500 kroner 100% 501-1000 kroner 50% 1,001-3,500 kroner 10%
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze